Catherine Soldano-Noble Executive Director, Marketing & Business Development Medpace, Inc. Cincinnati, OH 45212
Exhibit
4.91
Xxxxxxxxx
Xxxxxxx-Xxxxx
Executive
Director, Marketing & Business Development
Medpace,
Inc.
0000
Xxxxxx Xxxxxx
Xxxxxxxxxx,
XX 00000
Re: Amendment
#5 to the Letter Agreement (“Amendment #5”) for certain initial services for the
Ethyl-EPA Hypertriglyceridemia Studies between Amarin Pharma Inc., Amarin
Pharmaceuticals Ireland Limited, and Medpace, Inc. dated 1 December 2008, as
amended on 19 January 2009 and as further amended on 30 January 2009, 5 May 2009
and 3 August 2009 (the “Initial Services Letter Agreement”).
Dear
Xxxxxxxxx:
The
parties wish to amend the Initial Services Letter Agreement
in order to include new direct costs for Site Identification and
Selection for the 0017 study
This
Amendment #5 is dated as of the date of last signature below.
Defined
terms in this letter shall have the same meanings as given to such terms in the
Initial Services Letter Agreement unless otherwise defined herein
In
consideration of the mutual covenants contained in the Initial Services Letter
Agreement IT IS NOW HEREBY
AGREED AS FOLLOWS:
|
1.
|
Direct
Fees
|
|
·
|
Medpace
will perform CRF Development for the 0017 study, and Amarin will pay
Medpace $11,019.58 for this
service.
|
|
·
|
Medpace
will perform IVRS Development for the 0017 study, and Amarin will pay
Medpace $25,890.00 for this
service.
|
|
·
|
Medpace
will perform ICF services for the 0017 study, and Amarin will pay Medpace
$2,772.00 for this service.
|
|
·
|
Medpace
will Negotiate Site Budgets for the 0017 study, and Amarin will pay
Medpace $40,710.00 for this
service.
|
|
·
|
Medpace
will provide Study Master Files for the 0017 study, and Amarin will pay
Medpace $13,068.00 for this
service.
|
|
·
|
Medpace
will Collect Regulatory Documents for the 0017 study, and Amarin will pay
Medpace $70,136.93 for this
service.
|
|
·
|
Medpace
will perform Project Management for the 0017 study, and Amarin will pay
Medpace $99,566.71 for this
service.
|
|
·
|
Medpace
will conduct Teleconferences with the Sponsor for the 0017 study, and
Amarin will pay Medpace $2,568.00 for this
service.
|
|
·
|
Medpace
will perform Qualification Visits for the 0017 study, and Amarin will pay
Medpace $23,120.00 for this
service.
|
|
·
|
Medpace
will provide a Monitoring Plan for the 0017 study, and Amarin will pay
Medpace $1,106.80 for this service.
|
|
·
|
For
the Direct Fees listed above, Amarin will pay Medpace $289,958.01 for
the Initial
Trial 0017 Services Letter Agreement upon signature of this Amendment
#5.
|
|
2.
|
Pass
Through
|
|
·
|
Pass
Through costs for Monitoring Travel have been added in the amount of
$10,000.00.
|
|
·
|
Pass
Through costs for Conference Calls have been added in the amount of
$200.00.
|
|
·
|
For
the Pass Through costs listed above, Amarin will pay Medpace $10,200.00
for the Initial
Trial 0017 Services Letter Agreement upon signature of this Amendment
#5.
|
|
3.
|
Escrow
Fees
|
|
·
|
Escrow
Fees for Central IRB have been added in the amount of
$49,841.99.
|
|
·
|
For
the Escrow Fees listed above, Amarin will pay Medpace $49,841.99 for
the Initial
Trial 0017 Services Letter Agreement upon signature of this Amendment
#5.
|
All other
provisions of the Initial Services Letter Agreement shall remain unchanged and
in full force and effect.
Please
confirm your agreement with the above by signing this letter where indicated
below and returning a fully signed version to us.
Yours
sincerely,
Amarin
Pharma Inc.
by:___________________________________
Name:
Title:
Date:
Amarin
Pharmaceuticals Ireland Limited
by:___________________________________
Name:
Title:
Date:
AGREED
TO: Medpace, Inc.
by:___________________________________
Name:
Title:
Date:
